Biocidal Surfaces for Medical Hardware

描述(申请人提供)：美国每年有5%-10%的急性护理医院患者(175万-350万人)在住院期间感染。医院获得性(院内)感染的后果包括延长住院时间，增加患者的疼痛和不适，甚至死亡。每年由医院感染造成的死亡人数可能超过10万人。每年膨胀的医疗成本高达数十亿美元。感染的数量和严重程度正在增加，其中耐药菌株造成的感染比例更大。 人们普遍认为，卫生上的疏忽会导致感染，而无生命的物体可能会在微生物的传播中发挥作用。最近的实验室和临床研究表明，细菌可以在隐私窗帘、电脑键盘和医疗设备上的键盘等物品上存活数周甚至数月。需要在不增加人力的情况下防止微生物增殖和传播的技术，以补充其他感染控制做法，以改善患者结果。CCL Biomedical已经确定了一种独特的杀菌家族，它可以在接触时杀死细菌和其他微生物。该杀生剂可以在温和的条件下以化学方式附着在物品上。表面的化学附着减少了杀生剂向环境中的迁移。经过处理的表面将杀死任何停留在表面上的微生物。此外，杀菌剂不会被微生物消耗，这意味着处理可以提供持续的保护。 在第一阶段计划中，我们将用我们的生物杀灭化合物处理一些模型表面，并在实验室研究中使用临床相关细菌测试它们的抗菌效果。代表性材料包括玻璃、不锈钢、聚亚安酯和硅橡胶。在第二阶段，微生物学研究将扩大到包括病毒和霉菌。经过处理的表面将进行耐久性、迁移性和寿命测试。还将进行毒理学测试。通过开发杀生表面处理，我们的目标是在不增加医护人员和清洁人员的工作量的情况下，改善患者的结果。项目摘要每年，美国急性护理医院收治的患者中有5%-10%(175万-350万人)在住院期间感染。医疗保健行业的总成本高达数十亿美元，感染导致患者疼痛和不适加剧，每年约有10万人死亡。虽然感染控制最重要的方面是洗手，但无生命的物品可能会在感染的传播中发挥作用。我们建议开发一种可应用于医疗硬件和家具的解决方案，以降低可能在此类物品和手之间转移的微生物的生存能力。这将减少医院感染的数量。

DESCRIPTION (provided by applicant): Each year, 5-10% of patients admitted to acute care hospitals in the United States (1.75- 3.5 million people) acquire an infection while in hospital. Consequences of hospital-acquired (nosocomial) infections include prolonged hospital stays, increased pain and discomfort for the patient, and even death. The number of deaths per year caused by nosocomial infections may exceed 100,000. The inflated costs of healthcare run into billions of dollars annually. The number and severity of infections is increasing, with antibiotic resistant strains causing a greater proportion of those infections. It is widely accepted that lapses in hygiene can contribute to infections, and that inanimate objects can play a role in the transmission of microbes. Recent laboratory and clinical studies have shown that bacteria can survive for weeks and even months on items such as privacy curtains, computer keyboards, and keypads on medical equipment. Technologies that prevent the proliferation and transmission of microbes without an increase in manpower are needed to supplement other infection control practices to improve patient outcomes. CCL Biomedical has identified a unique biocidal family that kills bacteria and other microbes on contact. The biocide is can be chemically attached to articles under mild conditions. Chemical attachment to a surface reduces migration of the biocide into the environment. Treated surfaces will kill any microbes that settle on the surface. Furthermore, the biocide is not consumed by the microorganism, meaning that the treatment can provide continuous protection. During the Phase I program, we will treat a number of model surfaces with our biocidal compounds, and test them for antimicrobial effectiveness using clinically relevant bacteria in laboratory studies. Representative materials include glass, stainless steel, polyurethane, and silicone rubber. During Phase II, microbiological studies will be expanded to include viruses and molds. Treated surfaces will be tested for durability, migration, and longevity. Toxicological testing will also be performed. By developing biocidal surface treatments, we aim to improve the outcome for patients, without adding to the workload of healthcare workers and janitorial staff. Project Summary Each year, 5-10% of patients (1.75-3.5 million people) admitted to acute care hospitals in the United States acquire an infection while in hospital. The total cost to the healthcare industry runs in the billions of dollars, and infections result in increased pain and discomfort for the patient, and approximately 100,000 deaths per year. Although the most important aspect of infection control is hand-washing, inanimate items can play a role in the transmission of infection. We propose to develop a solution that can be applied to medical hardware and furnishings to reduce the viability of microbes that may be transferred between such items and the hands. This will reduce the number of hospital-acquired infections.